Get startedLog in
    Picture of CRISM Therapeutics logo

    CRTX — CRISM Therapeutics Income Statement

    0.000.00%
    gb flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for CRISM Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:
    fx
    Final
    fx
    Final
    fx
    Final
    fx
    Final    		Final
    Revenue
    Total Revenue00000.025
    Cost of Revenue
    Gross Profit————0.021
    Selling / General / Administrative Expenses
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses2.491.32.111.820.607
    Operating Profit-2.49-1.3-2.11-1.82-0.582
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-2.08-1.3-2.11-1.92-0.593
    Provision for Income Taxes
    Net Income After Taxes-2.08-1.3-2.11-1.92-0.593
    Net Income Before Extraordinary Items
    Extraordinary Items
    Net Income-2.08-0.877-2.45-7.76-0.607
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-2.08-0.877-2.45-7.76-0.607
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.273-0.128-0.208-0.221-0.028
    Special Dividends per Share